Laura Shawver, Ph.D., has more than 25 years of experience as a biotech executive in public and private companies. She has served on our Board of Directors and as our Board Chair since September 2025. Most recently, Dr. Shawver was President and CEO of Capstan Therapeutics (acquired by AbbVie). Her prior experience includes CEO of Silverback Therapeutics (acquired by ARS Pharma) and President and CEO of Synthorx (acquired by Sanofi). She has served on several Boards of public and private companies, currently serving on the Boards of ARS Pharma (Nasdaq: SPRY), Adcendo SpA (as Board Chair), and Dovetail Therapeutics. Dr. Shawver is the founder and director of The Clearity Foundation (now part of OCRA), a non-profit organization dedicated to improving treatment options for women with ovarian cancer. Dr. Shawver received her Ph.D. in Pharmacology and B.S. In Microbiology, both from the University of Iowa.
